- Email: [email protected]
Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Sq Nsclc Who Have Failed Previous Treatments
Annals of Oncology 25 (Supplement 5): v44–v74, 2014 doi:10.1093/annonc/mdu435.107
Oral Session (Oral presentations categorized by each organ) O3
9
1
Masahiro Kodani1, Tadashi Igishi1, Hirokazu Touge1, Yasuto Ueda1, Haruhiko Makino1, Hisashi Suyama2, Takashi Sumikawa2, Hirofumi Nakazaki3, Toshiyuki Tatsukawa4, Eiji Shimizu1 1 Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University 2 Tottori Prefectural Central Hospital 3 Matsue Red Cross Hospital 4 Matsue City Hospital
abstracts
Backgrounds: Bevacizumab (BEV) in combination with paclitaxel (PTX) and carboplatin (Cb) has provided survival benefit for advanced non-small cell lung cancer (NSCLC) as first-line treatment. However, tri-weekly PTX therapy induce severe
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v69/2240211 by guest on 24 October 2019
WEEKLY PACLITAXEL IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH Non-Sq NSCLC WHO HAVE FAILED PREVIOUS TREATMENTS
peripheral neuropathy frequently, and may deteriorate quality of life. Because of this toxicity, platinum plus pemetrexed regimen may be preferred as first-line treatment over Cb/PTX/BEV regimen. Weekly paclitaxel (w-PTX) regimen has proved to be effective and safe in a large number of clinical trials for advanced solid tumors. However, few clinical studies have focused on the comparison between w-PTX and tri-weekly PTX in advanced NSCLC. We previously reported that fractionated administration of paclitaxel may be less toxic and more active against advanced NSCLC in clinical trials. Furthermore, several studies have reported that combination chemotherapy of w-PTX and BEV proved survival benefit in patients with advanced breast cancer. Therefore, we conducted a phase II trial to evaluate the efficacy and toxicity for the combination chemotherapy of w-PTX and BEV in patients with advanced non-squamous (non-Sq) NSCLC who have failed previous treatment. Methods: Eligibility required ECOG performance status 0-2 and prior cytotoxic chemotherapy. The primary end point of the phase II study was the progression free survival (PFS). PTX was infused on days 1, 8 and 15, and BEV (15 mg/kg) was administered on day 1 of a 4-week cycle until PD. Toxicity evaluations were based on CTCAE (version 4). Results: Between September 2011 and January 2014 a total of 30 eligible patients were enrolled onto the study. Conclusions: This combination of w-PTX and BEV is both feasible and active in the treatment of patients with advanced non-Sq NSCLC. We will soon start a phase II study evaluating this combination as first-line treatment.
Oral Session (Oral presentations categorized by each organ) O3
9
1
Masahiro Kodani1, Tadashi Igishi1, Hirokazu Touge1, Yasuto Ueda1, Haruhiko Makino1, Hisashi Suyama2, Takashi Sumikawa2, Hirofumi Nakazaki3, Toshiyuki Tatsukawa4, Eiji Shimizu1 1 Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University 2 Tottori Prefectural Central Hospital 3 Matsue Red Cross Hospital 4 Matsue City Hospital
abstracts
Backgrounds: Bevacizumab (BEV) in combination with paclitaxel (PTX) and carboplatin (Cb) has provided survival benefit for advanced non-small cell lung cancer (NSCLC) as first-line treatment. However, tri-weekly PTX therapy induce severe
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v69/2240211 by guest on 24 October 2019
WEEKLY PACLITAXEL IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH Non-Sq NSCLC WHO HAVE FAILED PREVIOUS TREATMENTS
peripheral neuropathy frequently, and may deteriorate quality of life. Because of this toxicity, platinum plus pemetrexed regimen may be preferred as first-line treatment over Cb/PTX/BEV regimen. Weekly paclitaxel (w-PTX) regimen has proved to be effective and safe in a large number of clinical trials for advanced solid tumors. However, few clinical studies have focused on the comparison between w-PTX and tri-weekly PTX in advanced NSCLC. We previously reported that fractionated administration of paclitaxel may be less toxic and more active against advanced NSCLC in clinical trials. Furthermore, several studies have reported that combination chemotherapy of w-PTX and BEV proved survival benefit in patients with advanced breast cancer. Therefore, we conducted a phase II trial to evaluate the efficacy and toxicity for the combination chemotherapy of w-PTX and BEV in patients with advanced non-squamous (non-Sq) NSCLC who have failed previous treatment. Methods: Eligibility required ECOG performance status 0-2 and prior cytotoxic chemotherapy. The primary end point of the phase II study was the progression free survival (PFS). PTX was infused on days 1, 8 and 15, and BEV (15 mg/kg) was administered on day 1 of a 4-week cycle until PD. Toxicity evaluations were based on CTCAE (version 4). Results: Between September 2011 and January 2014 a total of 30 eligible patients were enrolled onto the study. Conclusions: This combination of w-PTX and BEV is both feasible and active in the treatment of patients with advanced non-Sq NSCLC. We will soon start a phase II study evaluating this combination as first-line treatment.